Ubiquitin-like protein conjugation and the ubiquiting-proteasome system as drug targets

Nature Reviews Drug Discovery

Volumn 10, Issue 1, 2011, Pages 29-46

  Bedford, Lynn ^a   Lowe, James ^b   Dick, Lawrence R ^c   Mayer, R John ^a   Brownell, James E ^c  

^a School of Biomedical Sciences   (United States)

^b UNIVERSITY OF NOTTINGHAM   (United Kingdom)

^c MILLENNIUM PHARMACEUTICALS INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BORTEZOMIB; CARFILZOMIB; CEP 18770; CEP 18870; CULLIN; I KAPPA B KINASE GAMMA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1; IPSI 001; MLN 9708; NEDD8 PROTEIN; ONX 0912; PR 047; PR 957; PROTEASOME; PROTEASOME INHIBITOR; PROTEIN MDM2; RAPAMYCIN; SALINOSPORAMIDE A; SUMO 1 PROTEIN; SUMO 2 PROTEIN; SUMO 3 PROTEIN; TOLL LIKE RECEPTOR 4; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED DEATH DOMAIN PROTEIN; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED FACTOR 2; UBIQUITIN; UBIQUITIN CONJUGATING ENZYME E2; UBIQUITIN PROTEIN LIGASE E3; UNCLASSIFIED DRUG; X LINKED INHIBITOR OF APOPTOSIS;

AUTOPHAGY; BONE DISEASE; BRAIN TUMOR; CATALYSIS; DEGENERATIVE DISEASE; DRUG CONJUGATION; DRUG HALF LIFE; DRUG PROTEIN BINDING; DRUG TARGETING; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME INHIBITION; HEART DISEASE; HEART PROTECTION; HEART VENTRICLE HYPERTROPHY; HUMAN; IMMUNITY; INFLAMMATION; ISCHEMIC HEART DISEASE; MANTLE CELL LYMPHOMA; MULTIPLE MYELOMA; NONHUMAN; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN FUNCTION; PROTEIN HOMEOSTASIS; REVIEW; SIGNAL TRANSDUCTION; UBIQUITINATION;

ANIMALS; DRUG DELIVERY SYSTEMS; DRUG DESIGN; ENZYME INHIBITORS; HUMANS; PROTEASOME ENDOPEPTIDASE COMPLEX; UBIQUITIN; UBIQUITINS;

EID: 78650824534     PISSN: 14741776     EISSN: 14741784     Source Type: Journal    
DOI: 10.1038/nrd3321     Document Type: Review

References (169)

1. Ciechanover, A, & Schwartz, A. L. The ubiquitin-proteasome pathway: the complexity and myriad functions of proteins death. Proc. Natl Acad. Sci. USA 95, 2727-2730 (1998).
2. Hoeller, D, & Dikic, I. Targeting the ubiquitin system in cancer therapy. Nature 458, 438-444 (2009).
3. Lehman, N. L. The ubiquitin proteasome system in neuropathology. Acta Neuropathol. 118, 329-347 (2009).
4. Corn, P. G. Role of the ubiquitin proteasome system in renal cell carcinoma. BMC Biochem. 8, S4 (2007).
5. Herrmann, J., Ciechanover, A., Lerman, L. O. & Lerman, A. The ubiquitin-proteasome system in cardiovascular diseases-a hypothesis extended. Cardiovasc. Res. 61, 11-21 (2004).
6. Petroski, M. D. The ubiquitin system, disease, and drug discovery. BMC Biochem. 9, S7 (2008).
7. Jin, J., Li, X., Gygi, S. P. & Harper, J. W. Dual E1 activation systems for ubiquitin differentially regulate E2 enzyme charging. Nature 447, 1135-1138 (2007).
8. Chiu, Y. H., Sun, Q. & Chen, Z. J. E1-L2 activates both ubiquitin and FAT10. Mol. Cell 27, 1014-1023 (2007).
9. Haglund, K., Di Fiore, P. P. & Dikic, I. Distinct monoubiquitin signals in receptor endocytosis. Trends Biochem. Sci. 28, 598-603 (2003).
10. Haglund, K., & Dikic, I. Ubiquitylation and cell signaling. EMBO J. 24, 3353-3359 (2005).
11. Mukhopadhyay, D. & Riezman, H. Proteasome-independent functions of ubiquitin in endocytosis and signaling. Science 315, 201-205 (2007).
12. Komander, D., Clague, M. J. & Urbe, S. Breaking the chains: structure and function of the deubiquitinases. Nature Rev. Mol. Cell Biol. 10, 550-563 (2009).
13. Sun, Y. Targeting E3 ubiquitin ligases for cancer therapy. Cancer Biol. Ther. 2, 623-629 (2003).
14. Singhal, S., Taylor, M. C. & Baker, R. T. Deubiquitylating enzymes and disease. BMC Biochem. 9, S3 (2008).
15. Schulman, B. A. & Harper, J. W. Ubiquitin-like protein activation by E1 enzymes: the apex for downstream signalling pathways. Nature Rev. Mol. Cell Biol. 10, 319-331 (2009).
16. Bohnsack, R. N. & Haas, A. L. Conservation in the mechanism of NEDD8 activation by the human AppBp1-Uba3 heterodimer. J. Biol. Chem. 278, 26823-26830 (2003).
17. Huang, D. T. et al. A unique E1-E2 interaction required for optimal conjugation of the ubiquitin-like protein NEDD8. Nature Struct. Mol. Biol. 11, 927-935 (2004).
18. Ye, Y. & Rape, M. Building ubiquitin chains: E2 enzymes at work. Nature Rev. Mol. Cell Biol. 10, 755-764 (2009).
19. Hochstrasser, M. Lingering mysteries of ubiquitin-chain assembly. Cell 124, 27-34 (2006).
20. Komander, D. et al. Molecular discrimination of structurally equivalent Lys 63-linked and linear polyubiquitin chains. EMBO Rep. 10, 466-473 (2009).
21. David, Y., Ziv, T., Admon, A. & Navon, A. The E2 ubiquitin conjugating enzymes direct polyubiquitination to preferred lysines. J. Biol. Chem. 285, 8595-8604 (2010).
22. Van Wijk, S. J., & Timmers, H. T. The family of ubiquitin-conjugating enzymes (E2s): deciding between life and death of proteins. FASEB J. 24, 981-993 (2010).
23. Petroski, M. D. & Deshaies, R. J. Function and regulation of cullin-RING ubiquitin ligases. Nature Rev. Mol. Cell Biol. 6, 9-20 (2005).
24. Aghajan, M. et al. Chemical genetics screen for enhancers of rapamycin identifies a specific inhibitor of an SCF family E3 ubiquitin ligase. Nature Biotech. 28, 738-742 (2010).
25. Orlicky S. et al. An allosteric inhibitor of substrate recognition by the SCF(Cdc4) ubiquitin ligase. Nature Biotech. 28, 733-737 (2010).
26. Ito, T. et al. Identification of a primary target of thalidomide teratogenicity. Science 327, 1345-1350 (2010).
27. Sowa, M. E., Bennett, E. J., Gygi, S. P. & Harper, J. W. Defining the human deubiquitinating enzyme interaction landscape. Cell 138, 389-403 (2009).
28. Bianchi, K. & Meier, P. A tangled web of ubiquitin chains: breaking news in TNF-R1 signaling. Mol. Cell 36, 736-742 (2009).
29. Chen, Z. J. & Sun, L. J. Nonproteolytic functions of ubiquitin in cell signaling. Mol. Cell 33, 275-286 (2009).
30. Tokunaga, F. et al. Involvement of linear polyubiquitylation of NEMO in NF-κB activation. Nature Cell Biol. 11, 123-132 (2009).
31. Haas, T. L. et al. Recruitment of the linear ubiquitin chain assembly complex stabilizes the TNF-R1 signaling complex and is required for TNF-mediated gene induction. Mol. Cell 36, 831-844 (2009).
32. Rahighi S. et al. Specific recognition of linear ubiquitin chains by NEMO is important for NF-κB activation. Cell 136, 1098-1109 (2009).
33. Laplantine, E. et al. NEMO specifically recognizes K63-linked poly-ubiquitin chains through a new bipartite ubiquitin-binding domain. EMBO J. 28, 2885-2895 (2009).
34. Xia, Z. P. et al. Direct activation of protein kinases by unanchored polyubiquitin chains. Nature 461, 114-119 (2009).
35. Vaux, D. L. & Silke, J. IAPs, RINGs and ubiquitylation. Nature Rev. Mol. Cell Biol. 6, 287-297 (2005).
36. Chen, A. et al. The HECT-type E3 ubiquitin ligase AIP2 inhibits activation-induced T-cell death by catalyzing EGR2 ubiquitination. Mol. Cell. Biol. 29, 5348-5356 (2009).
37. Komander, D. et al. The structure of the CYLD USP domain explains its specificity for Lys63-linked polyubiquitin and reveals a B box module. Mol. Cell 29, 451-464 (2008).
38. Wertz, I. E. et al. De-ubiquitination and ubiquitin ligase domains of A20 downregulate NF-κB signalling. Nature 430, 694-699 (2004).
39. Shembade, N., Ma, A. & Harhaj, E. W. Inhibition of NF-κB signaling by A20 through disruption of ubiquitin enzyme complexes. Science 327, 1135-1139 (2010).
40. Vereecke, L., Beyaert R. & Van Loo, G. The ubiquitin-editing enzyme A20 (TNFAIP3) is a central regulator of immunopathology. Trends Immunol. 30, 383-391 (2009).
41. Hymowitz, S. G. & Wertz, I. E. A20: from ubiquitin editing to tumour suppression. Nature Rev. Cancer 10, 332-341 (2010).
42. Cho, Y. S. et al. Phosphorylation-driven assembly of the RIP1-RIP3 complex regulates programmed necrosis and virus-induced inflammation. Cell 137, 1112-1123 (2009).
43. Zhang, D. W. et al. RIP3, an energy metabolism regulator that switches TNF-induced cell death from apoptosis to necrosis. Science 325, 332-336 (2009).
44. Degterev, A. et al. Identification of RIP1 kinase as a specific cellular target of necrostatins. Nature Chem. Biol. 4, 313-321 (2008).
45. Declercq, W., Vanden, B. T. & Vandenabeele, P. RIP kinases at the crossroads of cell death and survival. Cell 138, 229-232 (2009).
46. Xu, J. et al. NF-κB modulators in osteolytic bone diseases. Cytokine Growth Factor Rev. 20,7-17 (2009).
47. Dreger, H. et al. Nrf2-dependent upregulation of antioxidative enzymes: a novel pathway for proteasome inhibitor-mediated cardioprotection. Cardiovasc. Res. 83, 354-361 (2009).
48. Tsukamoto, O., Minamino, T. & Kitakaze, M. Functional alterations of cardiac proteasomes under physiological and pathological conditions. Cardiovasc. Res. 85, 339-346 (2010).
49. Yu, X. & Kem, D. C. Proteasome inhibition during myocardial infarction. Cardiovasc. Res. 85, 312-320 (2010).
50. Sohns, W., Van Veen, T. A. & Van Der Heyden, M. A. Regulatory roles of the ubiquitin-proteasome system in cardiomyocyte apoptosis. Curr. Mol. Med. 10, 1-13 (2010).
51. Enrico, O. et al. Unexpected cardiotoxicity in haematological bortezomib treated patients. Br. J. Haematol. 138, 396-397 (2007).
52. Luo, H., Wong J. & Wong, B. Protein degradation systems in viral myocarditis leading to dilated cardio-myopathy. Cardiovasc. Res. 85, 347-356 (2010).
53. Chen, P. C. et al. The proteasome-associated deubiquitinating enzyme Usp14 is essential for the maintenance of synaptic ubiquitin levels and the development of neuromuscular junctions. J. Neurosci. 29, 10909-10919 (2009).
54. Haas, K. F. & Broadie, K. Roles of ubiquitination at the synapse. Biochim. Biophys. Acta 1779, 495-506 (2008).
55. Dawson, T. M. & Dawson, V. L. The role of parkin in familial and sporadic Parkinson's disease. Mov. Disord. 25, S32-S39 (2010).
56. Dawson, T. M. Parkin and defective ubiquitination in Parkinson's disease. J. Neural Transm. Suppl. 209-213 (2006).
57. Bedford, L. et al. Depletion of 26S proteasomes in mouse brain neurons causes neurodegeneration and Lewy-like inclusions resembling human pale bodies. J. Neurosci. 28, 8189-8198 (2008).
58. Bedford, L. et al. Is malfunction of the ubiquitin proteasome system the primary cause of alpha-synucleinopathies and other chronic human neurodegenerative disease- Biochim. Biophys. Acta 1782, 683-690 (2008).
59. Hara, T. et al. Suppression of basal autophagy in neural cells causes neurodegenerative disease in mice. Nature 441, 885-889 (2006).
60. Komatsu, M. et al. Loss of autophagy in the central nervous system causes neurodegeneration in mice. Nature 441, 880-884 (2006).
61. Bedford, L. et al. The UPS and autophagy in chronic neurodegenerative disease: six of one and half a dozen of the other - or not? Autophagy 5, 224-227 (2009).
62. Matsuda, N. & Tanaka, K. Does impairment of the ubiquitin-proteasome system or the autophagy-lysosome pathway predispose individuals to neurodegenerative disorders such as Parkinson's disease- J. Alzheimers Dis. 19, 1-9 (2010).
63. Raiborg, C. & Stenmark, H. The ESCRT machinery in endosomal sorting of ubiquitylated membrane proteins. Nature 458, 445-452 (2009).
64. Rusten, T. E., Filimonenko, M., Rodahl, L. M., Stenmark, H. & Simonsen, A. ESCRTing autophagic clearance of aggregating proteins. Autophagy 4, 233-236 (2007).
65. Hetz, C. et al. XBP-1 deficiency in the nervous system protects against amyotrophic lateral sclerosis by increasing autophagy. Genes Dev. 23, 2294-2306 (2009).
66. Paine, S. et al. Immunoreactivity to Lys63-linked polyubiquitin is a feature of neurodegeneration. Neurosci. Lett. 460, 205-208 (2009).
67. McGowan, E., Eriksen, J. & Hutton, M. A decade of modeling Alzheimer's disease in transgenic mice. Trends Genet. 22, 281-289 (2006).
68. Melrose, H. L., Lincoln, S. J., Tyndall, G. M. & Farrer, M. J. Parkinson's disease: a rethink of rodent models. Exp. Brain Res. 173, 196-204 (2006).
69. Lee, B. H. et al. Enhancement of proteasome activity by a small-molecule inhibitor of USP14. Nature 467, 179-184 (2010).
70. Rubinsztein, D. C., Gestwicki, J. E., Murphy, L. O. & Klionsky, D. J. Potential therapeutic applications of autophagy. Nature Rev. Drug Discov. 6, 304-312 (2007).
71. Maruyama, H. et al. Mutations of optineurin in amyotrophic lateral sclerosis. Nature 465, 223-226 (2010).
72. Zhu, G., Wu, C. J. Zhao, Y. & Ashwell, J. D. Optineurin negatively regulates TNFalpha- induced NF-kappaB activation by competing with NEMO for ubiquitinated RIP. Curr. Biol. 17, 1438-1443 (2007).
73. Orlowski, R. Z. & Kuhn, D. J. Proteasome inhibitors in cancer therapy: lessons from the first decade. Clin. Cancer Res. 14, 1649-1657 (2008).
74. Lesniak, M. S. & Brem, H. Targeted therapy for brain tumours. Nature Rev. Drug Discov. 3, 499-508 (2004).
75. Scheffner, M., Werness, B. A., Huibregtse, J. M., Levine, A. J. & Howley, P. M. The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53. Cell 63, 1129-1136 (1990).
76. Hingamp, P. M., Arnold, J. E., Mayer, R. J. & Dixon, L. K. A ubiquitin conjugating enzyme encoded by African swine fever virus. EMBO J. 11, 361-366 (1992).
77. Zhu, Y. et al. Structure of a Shigella effector reveals a new class of ubiquitin ligases. Nature Struct. Mol. Biol. 15, 1302-1308 (2008).
78. Edelmann, M. J. & Kessler, B. M. Ubiquitin and ubiquitin-like specific proteases targeted by infectious pathogens: emerging patterns and molecular principles. Biochim. Biophys. Acta 1782, 809-816 (2008).
79. Chang, T. H. et al. Ebola Zaire virus blocks type I interferon production by exploiting the host SUMO modification machinery. PLoS Pathog. 5, e1000493 (2009).
80. Morita, E. & Sundquist, W. I. Retrovirus budding. Annu. Rev. Cell Dev. Biol. 20, 395-425 (2004).
81. Kyei, G. B. et al. Autophagy pathway intersects with HIV-1 biosynthesis and regulates viral yields in macrophages. J. Cell Biol. 186, 255-268 (2009).
82. Harty, R. N., Pitha, P. M. & Okumura, A. Antiviral activity of innate immune protein ISG15. J. Innate Immunol. 1, 397-404 (2009).
83. Zheng, Y. T. et al. The adaptor protein p62/SQSTM1 targets invading bacteria to the autophagy pathway. J. Immunol. 183, 5909-5916 (2009).
84. Thurston, T. L., Ryzhakov G., Bloor S., von Muhlinen, N. & Randow, F. The TBK1 adaptor and autophagy receptor NDP52 restricts the proliferation of ubiquitin-coated bacteria. Nature Immunol. 10, 1215-1221 (2009).
85. Yoshikawa, Y. et al. Listeria monocytogenes ActA-mediated escape from autophagic recognition. Nature Cell Biol. 11, 1233-1240 (2009).
86. Burns, K. E., Pearce, M. J. & Darwin, K. H. Prokaryotic ubiquitin-like protein provides a two-part degron to Mycobacterium proteasome substrates. J. Bacteriol. 192, 2933-2935 (2010).
87. World Health Organization. Fact sheet N.°104: Tuberculosis. WHO website [online], http://www.who. int/mediacentre/factsheets/fs104/en (2010).
88. Darwin, K. H., Ehrt, S., Gutierrez-Ramos, J. C., Weich, N. & Nathan, C. F. The proteasome of Mycobacterium tuberculosis is required for resistance to nitric oxide. Science 302, 1963-1966 (2003).
89. Pearce, M. J., Mintseris, J., Ferreyra, J., Gygi, S. P. & Darwin, K. H. Ubiquitin-like protein involved in the proteasome pathway of Mycobacterium tuberculosis. Science 322, 1104-1107 (2008).
90. Cerda-Maira, F. A. et al. Molecular analysis of the prokaryotic ubiquitin-like protein (Pup) conjugation pathway in Mycobacterium tuberculosis. Mol. Microbiol. 77, 1123-1135 (2010).
91. Burns, K. E. et al. "Depupylation" of prokaryotic ubiquitin-like protein from mycobacterial proteasome substrates. Mol. Cell 39, 821-827 (2010).
92. Wang, T. et al. Structural insights on the Mycobacterium tuberculosis proteasomal ATPase Mpa. Structure 17, 1377-1385 (2009).
93. Lin, G. et al. Mycobacterium tuberculosis prcBA genes encode a gated proteasome with broad oligopeptide specificity. Mol. Microbiol. 59, 1405-1416 (2006).
94. Hu, G. et al. Structure of the Mycobacterium tuberculosis proteasome and mechanism of inhibition by a peptidyl boronate. Mol. Microbiol. 59, 1417-1428 (2006).
95. Lin, G., Tsu, C., Dick, L., Zhou, X. K. & Nathan, C. Distinct specificities of Mycobacterium tuberculosis and mammalian proteasomes for N-acetyl tripeptide substrates. J. Biol. Chem. 283, 34423-34431 (2008).
96. Lin, G. et al. Inhibitors selective for mycobacterial versus human proteasomes. Nature 461, 621-626 (2009).
97. Walsh, R. C. et al. Proteasome inhibitor-based primary therapy for antibody-mediated renal allograft rejection. Transplantation 89, 277-284 (2010).
98. Borissenko, L. & Groll, M. 20S proteasome and its inhibitors: crystallographic knowledge for drug development. Chem. Rev. 107, 687-717 (2007).
99. Demo, S. D. et al. Antitumor activity of PR-171, a novel irreversible inhibitor of the proteasome. Cancer Res. 67, 6383-6391 (2007).
100. Zhou, H. J. et al. Design and synthesis of an orally bioavailable and selective peptide epoxyketone proteasome inhibitor (PR-047). J. Med. Chem. 52, 3028-3038 (2009).
101. Roccaro, A. M. et al. Selective inhibition of chymotrypsin-like activity of the immunoproteasome and constitutive proteasome in Waldenstrom macroglobulinemia. Blood. 11 5 4051-4060 (2010).
102. Chauhan, D. et al. A novel orally active proteasome inhibitor induces apoptosis in multiple myeloma cells with mechanisms distinct from Bortezomib. Cancer Cell 8, 407-419 (2005).
103. Kupperman, E. et al. Evaluation of the proteasome inhibitor MLN9708 in preclinical models of human cancer. Cancer Res. 70, 1970-1980 (2010).
104. Piva R. et al. CEP-18770: a novel, orally active proteasome inhibitor with a tumor-selective pharmacologic profile competitive with bortezomib. Blood 111, 2765-2775 (2008).
105. Dick, L. R. & Fleming, P. E. Building on bortezomib: second-generation proteasome inhibitors as anti-cancer therapy. Drug Discov. Today 15, 243-249 (2010).
106. Dorsey, B. D. et al. Discovery of a potent, selective, and orally active proteasome inhibitor for the treatment of cancer. J. Med. Chem. 51, 1068-1072 (2008).
107. Muchamuel, T. et al. A selective inhibitor of the immunoproteasome subunit LMP7 blocks cytokine production and attenuates progression of experimental arthritis. Nature Med. 15, 781-787 (2009).
108. Kuhn, D. J. et al. Targeted inhibition of the immunoproteasome is a potent strategy against models of multiple myeloma that overcomes resistance to conventional drugs and nonspecific proteasome inhibitors. Blood 113, 4667-4676 (2009).
109. Yang, Y. et al. Inhibitors of ubiquitin-activating enzyme (E1), a new class of potential cancer therapeutics. Cancer Res. 67, 9472-9481 (2007).
110. Xu, G. W. et al. The ubiquitin-activating enzyme E1 as a therapeutic target for the treatment of leukemia and multiple myeloma. Blood 11 5, 2251-2259 (2010).
111. Kitagaki, J. et al. Nitric oxide prodrug JS-K inhibits ubiquitin E1 and kills tumor cells retaining wild-type p53. Oncogene 28, 619-624 (2009).
112. Soucy, T. A. et al. An inhibitor of NEDD8-activating enzyme as a new approach to treat cancer. Nature 458, 732-736 (2009).
113. Soucy, T. A., Smith, P. G. & Rolfe, M. Targeting NEDD8-activated cullin-RING ligases for the treatment of cancer. Clin. Cancer Res. 15, 3912-3916 (2009).
114. Chiba, T. & Tanaka, K. Cullin-based ubiquitin ligase and its control by NEDD8-conjugating system. Curr. Protein Pept. Sci. 5, 177-184 (2004).
115. Duda, D. M. et al. Structural insights into NEDD8 activation of cullin-RING ligases: conformational control of conjugation. Cell 134, 995-1006 (2008).
116. Traore, T. et al. Pre-clinical antitumor activity of MLN4924, an inhibitor of NEDD8-activating enzyme (NAE), in a novel primary human DLBCL xenograft model. Blood 11 4, 382a (2009).
117. Swords, R. T. et al. Inhibition of NEDD8-activating enzyme: a novel approach for the treatment of acute myeloid leukemia. Blood 11 5, 3796-3800 (2010).
118. Brownell, J. E. et al. Substrate-assisted inhibition of ubiquitin-like protein activating enzymes: the NEDD8 E1 inhibitor MLN4924 forms a NEDD8-AMP mimetic in situ. Mol. Cell 37, 102-111 (2010).
119. Maeda, H. et al. Ubiquitin-conjugating enzyme UBE2Q2 suppresses cell proliferation and is down-regulated in recurrent head and neck cancer. Mol. Cancer Res. 7, 1553-1562 (2009).
120. Duan, X., Trent, J. O. & Ye, H. Targeting the SUMO E2 conjugating enzyme Ubc9 interaction for anti-cancer drug design. Anticancer Agents Med. Chem. 9, 51-54 (2009).
121. Mo, Y. Y. & Moschos, S. J. Targeting Ubc9 for cancer therapy. Expert Opin. Ther. Targets 9, 1203-1216 (2005).
122. Zhu, S. Sachdeva, M., Wu, F., Lu, Z. & Mo, Y. Y. Ubc9 promotes breast cell invasion and metastasis in a sumoylation-independent manner. Oncogene 29, 1763-1772 (2010).
123. Hao, J. et al. Elevated expression of UBE2T in lung cancer tumors and cell lines. Tumour Biol. 29, 195-203 (2008).
124. Van Ree, J. H., Jeganathan, K. B., Malureanu, L. & Van Deursen, J. M. Overexpression of the E2 ubiquitin-conjugating enzyme UbcH10 causes chromosome missegregation and tumor formation. J. Cell Biol. 188, 83-100 (2010).
125. Chen, S. et al. Association of clinicopathological features with UbcH10 expression in colorectal cancer. J. Cancer Res. Clin. Oncol. 136, 419-426 (2010).
126. Huang, A. et al. E2-c-Cbl recognition is necessary but not sufficient for ubiquitination activity. J. Mol. Biol. 385, 507-519 (2009).
127. Das, R. et al. Allosteric activation of E2-RING finger-mediated ubiquitylation by a structurally defined specific E2-binding region of gp78. Mol. Cell 34, 674-685 (2009).
128. Wu, P. Y. et al. A conserved catalytic residue in the ubiquitin-conjugating enzyme family. EMBO J. 22, 5241-5250 (2003).
129. Reyes-Turcu, F. E., Ventii, K. H. & Wilkinson, K. D. Regulation and cellular roles of ubiquitin-specific deubiquitinating enzymes. Annu. Rev. Biochem. 78, 363-397 (2009).
130. Love, K. R., Catic, A., Schlieker, C. & Ploegh, H. L. Mechanisms, biology and inhibitors of deubiquitinating enzymes. Nature Chem. Biol. 3, 697-705 (2007).
131. Cohn, M. A. et al. A UAF1-containing multisubunit protein complex regulates the Fanconi anemia pathway. Mol. Cell 28, 786-797 (2007).
132. Masuya, D. et al. The HAUSP gene plays an important role in non-small cell lung carcinogenesis through p53-dependent pathways. J. Pathol. 208, 724-732 (2006).
133. Trompouki, E. et al. CYLD is a deubiquitinating enzyme that negatively regulates NF-κB activation by TNFR family members. Nature 424, 793-796 (2003).
134. Liu, Y. et al. The UCH-L1 gene encodes two opposing enzymatic activities that affect alpha-synuclein degradation and Parkinson's disease susceptibility. Cell 111, 209-218 (2002).
135. Daviet, L. & Colland, F. Targeting ubiquitin specific proteases for drug discovery. Biochimie 90, 270-283 (2008).
136. Ghosh, A. K. et al. Structure-based design, synthesis, and biological evaluation of a series of novel and reversible inhibitors for the severe acute respiratory syndrome-coronavirus papain-like protease. J. Med. Chem. 52, 5228-5240 (2009).
137. Ratia, K. et al. A noncovalent class of papain-like protease/ deubiquitinase inhibitors blocks SARS virus replication. Proc. Natl Acad. Sci. USA 105, 16119-16124 (2008).
138. Sierra, M. I., Wright, M. H. & Nash, P. D. AMSH interacts with ESCRT-0 to regulate the stability and trafficking of CXCR4. J. Biol. Chem. 285, 13990-14004 (2010).
139. Tatsumi, K. et al. A novel type of E3 ligase for the Ufm1 conjugation system. J. Biol. Chem. 285, 5417-5427 (2010).
140. Wertz, I. E. & Dixit, V. M. Signalling to NF-κB: regulation by ubiquitin. Cold Spring Harb. Perspect. Biol. 2, a003350 (2010).
141. Gautheron, J. & Courtois, G. "Without Ub I am nothing": NEMO as a multifunctional player in ubiquitin-mediated control of NF-κB activation. Cell. Mol. Life Sci. 67, 3101-3113 (2010).
142. Herrmann, J., Lerman, L. O. & Lerman, A. Ubiquitin and ubiquitin-like proteins in protein regulation. Circ. Res. 100, 1276-1291 (2007).
143. Hochstrasser, M. Origin and function of ubiquitin-like proteins. Nature 458, 422-429 (2009).
144. Zhang, Z. et al. MDM2 is a negative regulator of p21WAF1/CIP1, independent of p53. J. Biol. Chem. 279, 16000-16006 (2004).
145. Vassilev, L. T. et al. In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science 303, 844-848 (2004).
146. Issaeva, N. et al. Small molecule RITA binds to p53, blocks p53-HDM-2 interaction and activates p53 function in tumors. Nature Med. 10, 1321-1328 (2004).
147. Gopal, Y. N., Chanchorn, E. & Van Dyke, M. W. Parthenolide promotes the ubiquitination of MDM2 and activates p53 cellular functions. Mol. Cancer Ther. 8, 552-562 (2009).
148. Cardozo, T. & Pagano, M. Wrenches in the works: drug discovery targeting the SCF ubiquitin ligase and APC/C complexes. BMC Biochem. 8, S9 (2007).
149. Latres, E., Chiaur, D. S. & Pagano, M. The human F box protein beta-Trcp associates with the Cul1/Skp1 complex and regulates the stability of beta-catenin. Oncogene 18, 849-854 (1999).
150. Read, M. A. et al. NEDD8 modification of cul-1 activates SCF(beta(TrCP)-dependent ubiquitination of IκBα. Mol. Cell Biol. 20, 2326-2333 (2000).
151. Srinivasula, S. M. & Ashwell, J. D. IAPs: what's in a name- Mol. Cell 30, 123-135 (2008).
152. Galban, S. & Duckett, C. S. XIAP as a ubiquitin ligase in cellular signaling. Cell Death Differ. 17, 54-60 (2010).
153. Neil, J. R., Tian, M. & Schiemann, W. P. X-linked inhibitor of apoptosis protein and its E3 ligase activity promote transforming growth factor-β-mediated nuclear factor-κB activation during breast cancer progression. J. Biol. Chem. 284, 21209-21217 (2009).
154. Carter, B. Z. et al. Triptolide sensitizes AML cells to TRAIL-induced apoptosis via decrease of XIAP and p53-mediated increase of DR5. Blood 111, 3742-3750 (2008).
155. Carter, B. Z. et al. Simultaneous activation of p53 and inhibition of XIAP enhance the activation of apoptosis signaling pathways in AML. Blood 11 5, 306-314 (2010).
156. Cummings, J. et al. Method validation and preliminary qualification of pharmacodynamic biomarkers employed to evaluate the clinical efficacy of an antisense compound (AEG35156) targeted to the X-linked inhibitor of apoptosis protein XIAP. Br. J. Cancer. 95, 42-48 (2006).
157. Sanduja, S., Kaza, V. & Dixon, D. A. The mRNA decay factor tristetraprolin (TTP) induces senescence in human papillomavirus-transformed cervical cancer cells by targeting E6-AP ubiquitin ligase. Aging (Albany NY). 1, 803-817 (2009).
158. Matsuura, T. et al. De novo truncating mutations in E6-AP ubiquitin-protein ligase gene (UBE3A) in Angelman syndrome. Nature Genet. 15, 74-77 (1997).
159. Rathmell, W. K. & Chen S. VHL inactivation in renal cell carcinoma: implications for diagnosis, prognosis and treatment. Expert Rev. Anticancer Ther. 8, 63-73 (2008).
160. Paltoglou, S. & Roberts, B. J. HIF-1alpha and EPAS ubiquitination mediated by the VHL tumour suppressor involves flexibility in the ubiquitination mechanism, similar to other RING E3 ligases. Oncogene 26, 604-609 (2007).
161. Van Hagen, M., Overmeer, R. M., Abolvardi, S. S. & Vertegaal, A. C. RNF4 and VHL regulate the proteasomal degradation of SUMO-conjugated hypoxia-inducible factor-2α. Nucleic Acids Res. 38, 1922-1931 (2010).
162. Sufan, R. I. et al. Oxygen-independent degradation of HIF-alpha via bioengineered VHL tumour suppressor complex. EMBO Mol. Med. 1, 66-78 (2009).
163. Nakamura, T. & Lipton, S. A. Cell death: protein misfolding and neurodegenerative diseases. Apoptosis 14, 455-468 (2009).
164. Alchanati, I. et al. The E3 ubiquitin-ligase Bmi1/ Ring1A controls the proteasomal degradation of Top2alpha cleavage complex - a potentially new drug target. PLoS One 4, e8104 (2009).
165. Adams, J. The proteasome: a suitable antineoplastic target. Nature Rev. Cancer. 4, 349-360 (2004).
166. Adams, J. The development of proteasome inhibitors as anticancer drugs. Cancer Cell 5, 417-421 (2004).
167. Altun, M. et al. Effects of PS-341 on the activity and composition of proteasomes in multiple myeloma cells. Cancer Res. 65, 7896-7901 (2005).
168. Kuhn, D. J. et al. Potent activity of carfilzomib, a novel, irreversible inhibitor of the ubiquitin-proteasome pathway, against preclinical models of multiple myeloma. Blood 110, 3281-3290 (2007).
169. Feling, R. H. et al. Salinosporamide A: a highly cytotoxic proteasome inhibitor from a novel microbial source, a marine bacterium of the new genus Salinospora. Angew. Chem. Int. Ed Engl. 42, 355-357 (2003).